Market Research Report
Hyperlipidemia Drug Market 2019-2025
|Published by||Orion Market Research Pvt Ltd||Product code||949570|
Delivery time: 2-3 business days
|Hyperlipidemia Drug Market 2019-2025|
|Published: June 12, 2020||Content info:||
Global Hyperlipidemia Drug Market Size, Share & Trends Analysis Report, By Drug Class (HMG-CoA Reductase Inhibitors (Statins), PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Fabric Acid Derivatives (Fibrates), Niacin (Nicotinic Acid), Bile Acid Sequestrants(BAS), Combination Therapy, and Others) and Forecast Period 2019-2025
The global hyperlipidemiadrug market is estimated to grow at a low CAGR during the forecast period.The increasing number of cholesterol patients is propelling the global hyperlipidemiadrug market. As per WHO, hypercholesterolemia is estimated to result in more than 2.6 million deaths each year. Almost 37.0% of adults in the US have high LDL-C levels. Yet, lesser than 50.0% of patients receive any form of treatment and approximately 33.0% of patients undergoing treatment are unable to achieve normal lipid levels.However, the side effects of hyperlipidemia drugs are restraining the growth of the market.
The global hyperlipidemia drug market is segmented based on the drug class. Based on the drug class the market is segmented into HMG-CoA reductase inhibitors (statins), PCSK9 inhibitors, cholesterol absorption inhibitors, fabric acid derivatives (fibrates), niacin (nicotinic acid), bile acid sequestrants(BAS), combination therapy and others.Geographically, theglobal hyperlipidemiadrug market is segmented based on the region including North America, Europe, Asia-Pacific, and the Rest of the world (RoW).
The major manufactures of the hyperlipidemiadrug includeAmgen Inc.,Bristol-Myers Squibb Co., Daiichi Sankyo Co., Ltd., Ionis Pharmaceuticals, Inc., Mylan N.V, GlaxoSmithKline PLC Pfizer, Inc.,Sanofi-Aventis S.A.,Merck & Co., Inc.,Dr.Reddy's Laboratories, Ltd. and others.These companies are continuously making efforts to provide innovative products in the market.For instance, in April 2019, TtheUS FDA also approved Sanofi's Praluent. It is used as an adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce LDL-C.
The market study of the global hyperlipidemiadrug market is incorporated by extensive primary and secondary research conducted by a research team. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.
Secondary Sources Include:
The report is intended for providers, suppliers, and distributors of hyperlipidemia drugs, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and will serve as a source for 360-degree analysis of the market.
The Report Covers: